STEREOTACTIC ABLATIVE BODY RADIATION -SABR: A NEW THERAPEUTIC OPTION FOR TREATMENT OF STAGE I LUNG CANCER

Sarit Appel, Zvi Symon

Research output: Contribution to journalReview articlepeer-review

Abstract

INTRODUCTION: Stereotactic ablative radiotherapy (SABR) also known as stereotactic body radiation therapy (SBRT) offers a new therapeutic option for stage 1 lung cancer that cannot undergo surgery due to co-morbidities or patient refusal. This treatment evolved in the last decade thanks to technologic advancement of radiation therapy planning and delivery that allow real time imaging of the tumor and real time position correction before every treatment. Ultra high doses of radiation cause ablation of the target with very low collateral scatter dose to surrounding tissue. Numerous phase I/II trials and institutional series have demonstrated efficacy of this treatment with over 90% control of tumors of 3 cm or less and 80-85% for larger tumors, very similar to surgical results. Data from trials have driven guidelines for safe administration, thus, when properly administered, toxicity is minimal. SABR treatment is administered routinely at the Chaim Sheba Medical Center and in other radiation centers in Israel.

Original languageEnglish
Pages (from-to)672-676
Number of pages5
JournalHarefuah
Volume155
Issue number11
StatePublished - 1 Nov 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'STEREOTACTIC ABLATIVE BODY RADIATION -SABR: A NEW THERAPEUTIC OPTION FOR TREATMENT OF STAGE I LUNG CANCER'. Together they form a unique fingerprint.

Cite this